

## Original article

# Is it possible to predict the evolution of IgAN? Validation of the IgA nephropathy progression calculator and its relationship with MEST-C score in our population<sup>☆</sup>

Luis Martín-Penagos<sup>a,\*</sup>, Adalberto Benito<sup>a</sup>, María Victoria Oviedo<sup>b</sup>,  
Covadonga López del Moral Cuesta<sup>a</sup>, Javier Martín López<sup>c</sup>,  
Javier Gómez Román<sup>c</sup>, Raquel López-Mejías<sup>d</sup>, Gema Fernandez-Fresnedo<sup>a</sup>,  
Juan Carlos Ruíz San Millán<sup>a</sup>, Emilio Rodrigo Calabia<sup>a</sup>

<sup>a</sup> Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Cantabria, Spain

<sup>b</sup> Servicio de Nefrología, Hospital Río Carrión, Palencia, Spain

<sup>c</sup> Servicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

<sup>d</sup> Fundación Instituto de Investigación Marqués de Valdecilla-IDIVAL, Santander, Cantabria, Spain

## ARTICLE INFO

## Article history:

Received 12 May 2018

Accepted 31 October 2018

Available online 16 October 2019

## Keywords:

IgA nephropathy

Prognostic prediction tools

Oxford score (MEST-C)

IgA Nephropathy Prognostic

Calculator

## ABSTRACT

**Introduction:** IgA nephropathy (IgAN) is the most common and heterogeneous glomerular nephropathy. Several strategies have been used to determine the risk of progression to ESRD. We evaluate the prognostic significance and correlate the IgAN progression calculator (IgANPC) and the Oxford/MEST-C score in our population.

**Material and methods:** We performed a retrospective study of biopsied patients with diagnosis of IgA nephropathy from 1990 to 2015. We classified the biopsies using MEST-C score and we correlated the score to clinical evolution. We also calculated the risk of progression with the online IgANPC at the time of the biopsy.

**Results:** We analyzed 48 biopsies, 83% of which were men with a mean age of 45 years at the time of the biopsy.

Patients with a biopsy E1 according to MEST-C score had a higher IgANPC score than those with E0 ( $p = .021$ ).

The Pearson's correlation for the percentage of crescents and the IgANPC risk score was statistically significant ( $p = .014$ ) with  $r = 0.357$ .

The percentage of patients with eGFR above 30 ml/min at 10 years was 100% for the low-risk group (group 1 of IgANPC), and 0% for the high-risk group (group 3), log rank  $p = 0.001$ .

DOI of original article:

<https://doi.org/10.1016/j.nefro.2018.10.015>.

<sup>☆</sup> Please cite this article as: Martín-Penagos L, Benito A, Oviedo MV, López del Moral Cuesta C, Martín López J, Gómez Román J, et al. ¿Es posible predecir la evolución de la nefropatía IgA? Validamos la calculadora de progresión de nefropatía IgA y su relación con Oxford score en nuestra población. Nefrología. 2019;39:523–530.

\* Corresponding author.

E-mail address: [luis.martinp@scsalud.es](mailto:luis.martinp@scsalud.es) (L. Martín-Penagos).

2013-2514/© 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The log rank comparison for variables of the MEST-C score, presented statistically significant results between E (0.036) and S (0.022) and the eGFR time < 30 ml/min.

A statistically significant relationship was also observed between T1 and eGFR < 30 ml/min.

The multivariate Cox regression analysis for IgANPC and eGFR < 30 ml/min demonstrated a strong correlation ( $p = .016$ ) between the risk group and eGFR < 30 ml/min.

**Conclusion:** In our study population, the IgANPC predicts the time to eGFR < 30 ml/min, and adds information independent of the MEST.

The MEST-C classification and IgANPC are useful and independent tools for prognostic prediction, but more studies are needed to validate its use in the general population.

© 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## ¿Es posible predecir la evolución de la nefropatía IgA? Validamos la calculadora de progresión de nefropatía IgA y su relación con Oxford score en nuestra población

### R E S U M E N

#### Palabras clave:

Nefropatía IgA  
Herramientas de predicción  
pronóstica  
Oxford score (MEST-C)  
IGA Nephropathy Prognostic  
Calculator

**Introducción:** La nefropatía IgA es la enfermedad glomerular más frecuente y heterogénea. Hay estrategias histológicas y clínicas para determinar la progresión a ESRD.

Valoramos el significado pronóstico de la clasificación de Oxford/MEST-C y la calculadora de progresión de la NIgA (IgANPC) en nuestra población y relacionamos ambas herramientas.

**Material y métodos:** Realizamos un estudio retrospectivo de biopsias NIgA de 1990 hasta 2015. Se realizó el MEST de las biopsias y se calculó el riesgo de progresión con IgANPC. Se relaciona con la evolución clínica.

**Resultados:** Se analizaron 48 biopsias, 83% varones de 45 años de media.

La correlación entre el MEST-C y el IgANPC score a la biopsia mostró una concordancia entre pacientes con un score IgANPC alto y E1 ( $p = 0,021$ ).

La correlación de Pearson para el porcentaje de semilunas y el IgAPC es estadísticamente significativo ( $p = 0,014$ ) con  $r = 0,357$ .

El 100% de los pacientes clasificados en el grupo 1 de IgANPC mantienen un FG  $> 30$  ml/min a 10 años, mientras que ninguno de los del grupo 3 presenta un FG  $> 30$  ml/min a 10 años ( $p = 0,001$ ).

La comparación de log rank para variables del MEST-C score presenta resultados estadísticamente significativos entre E (0,036) y S (0,022), y el tiempo a FG  $< 30$  ml/min.

También se observa una relación estadísticamente significativa entre T1 y FG  $< 30$  ml/min. El análisis multivariante con la regresión de Cox para IgANPC y FG  $< 30$  ml/min muestra una fuerte correlación ( $p = 0,016$ ) entre el grupo de riesgo y FG  $< 30$  ml/min.

**Conclusión:** IgANPC predice el tiempo hasta FG  $< 30$  ml/min y añade información independiente del MEST.

La clasificación de MEST-C score y el IgANPC score son útiles e independientes para la predicción pronóstica; queda validar su uso en la población general.

© 2019 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

IgA glomerulonephritis, first described by Berger and Hinglais in 1968,<sup>1</sup> was described as a very frequent glomerular disease with a benign course<sup>2</sup>; nowadays we know that it is not this is not totally true.

In IgA nephropathy, sometimes the clinical course may be indolent, and hematuria may be the only manifestation of the disease for many years and without progression over time. However a significant number of patients, up to 40% in some series, progress over the years toward a chronic kidney disease, eventually requiring renal replacement therapy after

decades. Occasionally, the disease progresses more rapidly to end-stage renal disease in months or a few years.<sup>3,4</sup>

Thus, there is variability with respect to progression and prognosis of this disease, initially considered a benign entity but today we know that this is not the case, being the most frequent primary glomerular disease leading to dialysis.<sup>5,6</sup>

In recent years different prognostic tools have been developed to predict the risk of end-stage renal disease in patients diagnosed with IgA nephropathy.<sup>7</sup> Those showing the greatest relationship with progression are based on histology, such as the Oxford/MEST score<sup>8</sup> classification, completed in recent years by the association of crescents (to the score MEST, named MEST-C<sup>9</sup>). These are invasive techniques, requiring renal biopsy.

Also recently, non-invasive clinical tools to predict progression of the disease have been described. One of them is the IgA nephropathy progression calculator (IgANPC),<sup>10</sup> only validated in the Chinese population, which includes 4 clinical and analytical parameters at the diagnosis of the disease. However, a validated tool to predict the progression of this entity is not yet available in the general population.

In the present study we analyze the prediction capacity of the IgANPC in our population, as well as its link with the MEST-C classification, relating the different MEST-C variables with this calculator.

## Material and methods

During the last 25 years we have performed 866 kidney biopsies in patients from our center. The reference area of our hospital for renal biopsies currently includes the entire province of Cantabria and Río Carrión Palencia Hospital Complex; years ago it also included the Bierzo hospital in León, so in our study there are also some patients from these regions.

This is a retrospective study using all patients with kidney biopsy from 1990 to 2015. Of these, 108 patients were diagnosed of IgA glomerulonephritis. Analytical, clinical and demographic data was collected. Patients not included in the analysis were those with incomplete follow-up ( $n=17$ ), less than 18 years old ( $n=11$ ) and those with incomplete data in their records ( $n=32$  patients of the hospital El Bierzo and Río Carrión). For patients of Palencia that did have a correct follow-up, we had the collaboration of the Nephrology Service of the Río Carrión Hospital. A total of 48 patients were analyzed.

The following demographic, clinical and biochemical parameters in blood and urine were collected: age, height, weight, systolic blood pressure (SBP) and diastolic blood pressure, presence or absence of macroscopic hematuria, creatinine, CKD-EPI, serum albumin, uric acid, hemoglobin, 24 h proteinuria, protein/creatinine ratio in an urine sample, hemoglobinuria and hematuria in the urinary sediment. All this information was obtained at the time of the kidney biopsy, 2 years after and at the end of the follow-up or initiation of renal replacement therapy (RRT). The time at which the glomerular filtration rate (GFR) fell below 30 ml/min or the initial value of serum creatinine doubled were also collected.

Regarding the histology data, the following parameters were collected: the number of glomeruli, the number of sclerosed glomeruli and the variables of the MEST, the percentage

of crescents and the presence of C4d and C3 by immunofluorescence.

All biopsies were reviewed and reclassified according to the Oxford/MEST-C criteria with the help of our Pathology Department.

In addition, the risk of progression was calculated using the online calculator IgANPC ([http://www.columbiamedicine.org/divisions/gharavi/calc\\_progression.php](http://www.columbiamedicine.org/divisions/gharavi/calc_progression.php)). This calculator is based on 4 parameters, both clinical and biochemical, obtained at the time of the kidney biopsy. The parameters on which it is based are: GFR, serum hemoglobin (g/dl), serum albumin (g/dl) and systolic blood pressure (mmHg). Depending on the values obtained, patients are classified as low risk ( $<-0.887$ ), medium (between  $-0.887$  and  $0.993$ ) or high ( $>0.993$ ), and the result of this calculator was recorded.

## Statistic analysis

Continuous variables are shown as mean  $\pm$  standard deviation, and qualitative variables are expressed as frequency and percentage.

The Mann–Whitney *U* test was used for comparison of quantitative variables of the MEST-C and the IgANPC scores. The Kruskal–Wallis test was used in the case of the variable time T (T0, T1 and T2 to define the degree of fibrosis and tubulo-interstitial atrophy).

The IgANPC score as a continuous variable was correlated with the percentage of crescents and the number of sclerosed glomeruli using Pearson correlation test.

The log rank comparison test was applied for variables of the MEST-C score and the time elapsed to reach end stage renal disease (ESRD).

Cox regression analysis was used to relate the different variables of the MEST-C score with the time elapsed to ESRD.

Kaplan–Meier curves were performed to determine the influence of the score on the progression to advanced chronic renal disease (estimated GFR  $<30$  ml/min).

The SPSS for Windows version 15.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.

## Results

In our renal biopsies, IgA constitutes 12% of the diagnosis. The percent of males and female was 83% and 17%, respectively. The average age at the time of the biopsy was 45.3 years, with a standard deviation of 20.8 years. The mean serum creatinine was 2 mg/dl with eGFR of  $62.1 \pm 43.3$  ml/min (Table 1).


Based on the score obtained with the IgANPC, patients were classified into 3-risk groups. In the low risk group there were 25% of patients, in the intermediate and high risk groups 27.1% and 47.9% respectively. After 10 years, all patients classified in the low-risk group (group 1) of IgANPC maintain a eGFR  $>30$  ml/min while in the medium risk group (group 2) only 68.6% had eGFR  $>30$  ml/min and none of the patients in the high risk group (group 3) have a eGFR  $>30$  ml/min at 10 years ( $p=0.001$ ) (Fig. 1).

After reclassifying the biopsies using the MEST-C, the percent of patients in M1 was 83%, being 35% in E1, 39.6% in S1 and T0 47.9%, T1 39.6% and T2 12.5%.

**Table 1 – Description of the patients characteristics.**


	Mean	Median	SD	Minimum	Maximum	25th percentile	50th percentile	75th percentile
Age (years)	45.3	44.5	20.4	18	80	28.2	44.5	65.7
Glomeruli number	15.4	15.0	8.7	2	38	8.0	15.0	20.0
Sclerosed glomeruli number	2.26	1.00	2.64	0	12	0.0	1.00	3.0
% crescents	11.4	0.00	20.5	0	78	0.0	0.0	14.0
Creatinine Bx. (mg/dl)	2.06	1.54	0.53	0.50	7.8	0.9	1.54	2.90
Serum albumin (g/dl)	3.69	3.65	0.87	1.6	7.5	3.2	3.6	4.2
eGFR Bx. (ml/min)	62.11	51.0	43.3	2.0	165	22	51.0	100.0
SBP (mmHg)	141	139	21.3	100	200	128	139	150
DBP (mmHg)	79	80	15.0	50	120	70	80	90

Influencia del score en alcanzar filtrado glomerular estimado menor de 30 ml/min



**Figure 1 – Group 3, with a highest score, has a 100% chance of reaching FGe < 30 ml/min. The higher the score group, the greater the probability of advanced chronic renal failure.**

Asociación de Hipercelularidad endocapilar (E-Oxford) con IgANPC



**Figure 2 – The variable E1 of the Oxford/MEST classification is directly related with the score obtained with the IgANPC calculator and the association is statistically significant.**

The relationship between the value of each MEST-C variable and the probability of progression calculated using the IgANPC was analyzed. It was observed a concordance between patients with a high IgANPC score and E1 ( $p=0.021$ ). Likewise, we found a relationship between the score and T ( $p=0.026$ ); the higher the score, the greater the tubulo-interstitial

atrophy (Figs. 2 and 3). The rest of the MEST-C variables were not statistically related to the IgANPC score.

There was a significant correlation (Pearson's correlation) between the percentage of crescents and the IgANPC ( $r=0.375$ ,  $p=0.014$ ). No significant correlations were found between the other variables (Fig. 4).

Asociación de atrofia y fibrosis túbulo-intersticial (T-Oxford) con IgANPC




Figure 3 – Regarding the variable T of the Oxford/MEST classification, with its 3 possible values, T1, T2 and T3, the greater T (tubulo-interstitial atrophy), the higher score, being the result statistically significant.

		SCORERiesgoCalculado	N°GlomSCL	BxSemil
SCORERiesgoCalculado	Correlación de Pearson Sig. (bilateral)	1	,371*	,357*
	N	48	47	47
N°GlomSCL	Correlación de Pearson Sig. (bilateral)	,371*	1	,074
	N	47	47	46
BxSemil	Correlación de Pearson Sig. (bilateral)	,357*	,074	1
	N	47	46	47

\*. La correlación es significativa al nivel 0,05 (bilateral).




Figure 4 – Pearson’s correlation for glomerular sclerosis and percentage of crescents with IgANPC (calculated score).


By log rank test the period of time elapsed until reaching ESRD was significantly related to MEST-C score variables E ( $p < 0.036$ ) and S ( $p < 0.022$ ).

Cox regression analysis shows that ESRD is significantly related with IgANPC ( $p = 0.028$ ) (HR = 1.864 (95% CI, 1.127–3.083)). ESRD is also related with T1 (HR = 4.465; 95% CI, 1.179–16.905). Multivariate analysis shows a strong correlation between IgANPC with eGFR < 30 ml/min and the risk group ( $p = 0.016$ ) (HR = 13.701; CI 95%, 1.644–114.209).

Patients with the highest histological variables of E and T (the MEST groups of E1 and T2 and T3) showed a higher risk of reaching eGFR < 30 ml/min ( $p = 0.016$  and  $p = 0.001$ , respectively).

The multivariate analysis showed that the IgANPC score is independently related with a higher risk of developing a eGFR < 30 ml/min (HR = 13.701; 95% CI, 644–114.209;  $p = 0.016$ ).

The ROC curve predicting eGFR < 30 ml/min by IgANPC score shows an area under the curve of 0.843 which indicates



**Figure 5** – ROC curve to analyze the ability of the test to predict an eGFR of less than 30 ml/min based on the IgANPC score. AUC = 0.843.

that the test is a good predictor (between 0.75 and 0.90) of progression to advanced renal disease (Fig. 5).

## Discussion and conclusions

The IgA glomerulonephritis is underdiagnosed and its evolution is heterogeneous. Factors strongly related to the progression to ESRD are the presence of persistent proteinuria 1.000 mg/24 h, hypertension (BP > 140/90 mmHg) and elevated serum creatinine<sup>11-14</sup>; the patients who combine the high creatinine and proteinuria have the greatest risk of progression, presenting ESRD in 15–25% after 10 years, and 20–30% after 20 years of follow-up.<sup>15-18</sup> The persistence of hematuria has been also associated with a poor prognosis in different studies.<sup>19-23</sup>

There is evidence that many patients with IgA glomerulonephritis have a deficit in the glycosylation of the IgA1 molecule and this abnormality may be an important factor in the genesis of this disease.<sup>24-31</sup>

Yanagawa et al. demonstrated that galactosyl-deficient anti-IgA IgG present an area under the ROC curve of 0.813 to discriminate IgA nephropathy from other autoimmune causes of chronic renal diseases.<sup>32</sup> Recently, galactosyl-deficient IgA has also been related to renal prognosis in patients with IgA nephropathy.<sup>33-35</sup>

Different groups have used these serological markers to assess disease activity and their response to different treatments. Berthelot et al. demonstrated that levels of IgA1 galactosyl-deficient, anti-IgA galactosyl-deficient IgG and the soluble CD89-IgA complex predicts recurrence after renal transplantation.<sup>36</sup> Other groups have observed that steroid treatment reduces levels of galactosyl-deficient IgA1, while the use of rituximab does not decrease levels of galactosyl-deficient IgA1 and galactosyl-deficient IgA IgG, which could explain its lack of efficacy to treat IgA nephropathy.<sup>37,38</sup> The possibility of having a future treatment of IgA nephropathy, as observed in some animal models, using of recombinant

IgA1 protease makes these serological markers available of maximum interest<sup>39</sup> to monitor this nephropathy.

Given the frequency of IgA nephropathy, it is necessary to have tools that allow us to know in the best non-invasive way, the probability of progression to ESRD to help the clinician to select patients susceptible to treatment and also give the most accurate information about the prognosis at the time of diagnosis. The prognostic tools available today are clearly insufficient and all input is welcome.

In the present study, we have not directly analyzed the classic parameters that have been related to progression, although creatinine and hypertension are included in the IgANPC, since the calculation is made based on eGFR, Systolic blood pressure, albumin and serum hemoglobin.

Regarding proteinuria, persistent hematuria and other markers that have been classically associated with prognosis and MEST,<sup>40-42</sup> it has not been the subject of analysis in this work.

In 2014, a work by the VALIGA group of the ERA-EDTA by Coppo et al. in *Kidney International*, different variables of the MEST are related with the prognosis of IgA nephropathy. In this work, a greater value of the variables M, S and T is related to a worse prognosis, and this association is independent of other variables. When the histological changes of the MEST are related to clinical variables such as proteinuria, the prognostic capacity of the test increases significantly in the group of untreated patients.<sup>41</sup>

We have demonstrated in our group of patients that the IgANPC is an adequate tool to predict the period of time to reach FG < 30 ml/min, and adds prognostic information independent of the MEST-C. In addition, this is a non-invasive tool that, unlike MEST-C, does not require a renal biopsy for its calculation. It also allows us to give concrete prognostic figures regarding the risk of developing ERCT or the need for renal replacement therapy, by expressing its result in a percentage. The latter allows the clinician to inform the patient about the prognosis in a clear and understandable way based

not only in professional experience but also on a standardized tool.

In recent years, the MEST classification has been optimized by adding the percentage of crescents to this score.<sup>9</sup> Our study confirms that this is correct, we found that the group with high-risk of progression of the disease had a higher percentage of lesions with extracapillary proliferation.

We can conclude that the classification of MEST-C score and the IgANPC score are useful and independent tools for prognostic prediction, it is necessary to validate their use in the general population and relate them to the available serological markers.

### Limitations of the study

First, this study is a retrospective analysis, with the biases inherent to this type of analysis. Nevertheless, it is the first study to evaluate and match IgANPC and MEST-C score in our population. Second, the number of patients analyzed is low, so the power of statistical results obtained is limited. Third, our data refers to the population of Cantabria and Palencia in Spain, therefore, they cannot be completely extrapolated to other geographical areas. Fourth, the clinical follow-up of the patients was very uneven in time (with a dispersion of 2 years the least follow-up, and 22 years the longest), which may be related to the absence of differences in the variables of clinical assessment between the study groups.

### Conflict of interests

The authors declare no conflict of interest.

### REFERENCES

- Berger J, Hinglais N. Les depots intercapillaires d'IgA-IgG. *J Urol Nephrol*. 1968;74:694–5.
- Bodian M, Black JA, Kobayashi N, Lake BD, Schuler SE. Recurrent haematuria in childhood. *Quart J Med*. 1965;34:359–82.
- D'Amico G, Colasanti G, Barbiano di Belgioioso G, Fellin G, Ragni A, Egidi F, et al. Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients. *Semin Nephrol*. 1987;7:355–8.
- Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. *J Am Soc Nephrol*. 1997;8:199–207.
- Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literatura. *Medicine (Baltimore)*. 1994;73:79–102.
- Briganti EM, Dowling J, Finlay M, Hill PA, Jones CL, Kincaid-Smith PS, et al. The incidence of biopsyproven glomerulonephritis in Australia. *Nephrol Dial Transplant*. 2001;16:1364–7.
- Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA. Prognostic indicators in children with IgA nephropathy—report of the Southwest Pediatric Nephrology Study Group. *Pediatr Nephrol*. 1994;8:15–20.
- Roberts ISD, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. *Kidney Int*. 2009;76:546–56. <http://dx.doi.org/10.1038/ki.2009.168>.
- Markowitz G. Glomerular disease: Updated Oxford Classification of IgA nephropathy: a new MEST-C score. *Nat Rev Nephrol*. 2017;13:385–6. <http://dx.doi.org/10.1038/nrneph.2017.67>.
- Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. *PLOS ONE*. 2012;7:e38904.
- Szeto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. *Am J Med*. 2001;110:434.
- Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance. *Kidney Int*. 1991;40:1050.
- Nozawa R, Suzuki J, Takahashi A, Isono M, Kawasaki Y, Suzuki S, et al. Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. *Clin Nephrol*. 2005;64:171.
- Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S, et al. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. *Am J Kidney Dis*. 2006;47:761.
- D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. *Am J Kidney Dis*. 1992;20:315.
- Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. *Am J Kidney Dis*. 1991;18:12.
- Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. *Nephrol Dial Transplant*. 2006;21:2800.
- Chacko B, John GT, Neelakantan N, Korula A, Balakrishnan N, Kirubakaran MG, et al. Presentation, prognosis and outcome of IgA nephropathy in Indian adults. *Nephrology (Carlton)*. 2005;10:496.
- Gutiérrez E, González E, Hernández E, Morales E, Martínez MA, Usera G, et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. *Clin J Am Soc Nephrol*. 2007;2:51–7.
- Moreno JA, Yuste C, Gutiérrez E, Sevillano AM, Rubio-Navarro A, Amaro-Villalobos JM, et al. Haematuria as a risk factor for chronic kidney disease progression in glomerular diseases: a review. *Pediatr Nephrol*. 2016;31:523–33.
- Gutiérrez E, Praga M, Rivera F, Sevillano A, Yuste C, Goicoechea M, et al. Changes in the clinical presentation of immunoglobulin A nephropathy: data from the Spanish Registry of Glomerulonephritis. *Nephrol Dial Transplant*. 2018;33:472–7.
- Sevillano AM, Gutiérrez E, Yuste C, Caverio T, Mérida E, Rodríguez P, et al. Remission of hematuria improves renal survival in IgA nephropathy. *J Am Soc Nephrol*. 2017;28:3089–99.
- Coppo R, Fervenza FC. Persistent microscopic hematuria as a risk factor for progression of IgA nephropathy: new floodlight on a nearly forgotten biomarker. *J Am Soc Nephrol*. 2017;28:2831–4.
- Hiki Y, Tanaka A, Kokubo T, Iwase H, Nishikido J, Hotta K, et al. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *J Am Soc Nephrol*. 1998;9:577–82.

25. Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). *Kidney Int.* 2004;65:1544-7.
26. Giannakakis K, Feriozzi S, Perez M, Faraggiana T, Muda AO. Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy. *J Am Soc Nephrol.* 2007;18:3139-46.
27. Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. *Kidney Int.* 2007;71:1148.
28. Monteiro RC, van de Winkel JG. IgA Fc receptors. *Annu Rev Immunol.* 2003;21:177-204.
29. Berger J, Hinglais NL. Les depots intercapillaires d'IgA IgG. *J Urol Nephrol.* 1968;74:694-5.
30. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. *Semin Nephrol.* 2004;24:179-96.
31. Monteiro RC. New insights in the pathogenesis of IgA nephropathy. *Nefrologia.* 2005;25 Suppl. 2:82.
32. Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. *PLOS ONE.* 2014;9, e98081.
33. Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. *Kidney Int.* 2012;82:790-6.
34. Coppo R, Fonsato V, Balegno S, Ricotti E, Loiacono E, Camilla R, et al. Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. *Kidney Int.* 2010;77:417-27.
35. Nguyen C, König K, Tam FWK, Hopfer H, Molyneux K, Binet FI, et al. Higher serum galactose-deficient immunoglobulin A1 concentration is associated with stronger mesangial cellular inflammatory response and more severe histologic findings in immunoglobulin A nephropathy. *Clin Kidney J.* 2018, 1-7. doi:10.1093/ckj/sfy068.
36. Berthelot L, Robert T, Vuiblet V, Tabary T, Braconnier A, Dramé M, et al. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. *Kidney Int.* 2015;88:815-22.
37. Kim MJ, Schaub S, Molyneux K, Koller MT, Stampf S, Barratt J. Effect of immunosuppressive drugs on the changes of serum galactose-deficient IgA1 in patients with IgA nephropathy. *PLOS ONE.* 2016;11, e0166830.
38. Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. *J Am Soc Nephrol.* 2017;28:1306-10.
39. Lechner SM, Abbad L, Boedec E, Papista C, Le Stang MB, Moal C, et al. IgA1 protease treatment reverses mesangial deposits and hematuria in a model of IgA nephropathy. *J Am Soc Nephrol.* 2016;27:2622-9.
40. Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, et al. The MEST score provides earlier risk prediction in IgA nephropathy. *Kidney Int.* 2016;89:167-75.
41. Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. *Kidney Int.* 2014;86:828-36.
42. Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford Classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. *Kidney Int.* 2017;91:1014-21.